ClinicalTrials.gg
CompletedNCT03403634Updated Mar 2, 2022Results posted

Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver

A Phase 2 interventional study of Celecoxib and Laboratory Biomarker Analysis in Metastatic Carcinoma in the Liver, Recurrent Colorectal Carcinoma and Stage IV Colorectal Cancer AJCC v7, sponsored by Roswell Park Cancer Institute. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-02.

Sponsored by Roswell Park Cancer Institute · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
19
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 28 studies testing celecoxib in Colorectal Neoplasms — 1 open to participants now, 1 under way, none of them phase 3. Celecoxib · Colorectal Neoplasms.

Enrollment
15th of 24
19 · median 23
Started
2018
the only one that year
Phase 2
15 of 28
1 open now
Registered
26th of 28
by date
Lead sponsor
3 of 28
Roswell Park Cancer Institute

Among the 28 studies testing celecoxib in Colorectal Neoplasms, this one is the 15th largest by enrollment of the 24 interventional ones that give a count, is the only one that started in 2018, is one of 15 in phase 2, and was the 26th registered.

Colorectal Neoplasms

6,554 studies on the registry are indexed under Colorectal Neoplasms; 1,665 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

1 of the 28 studies testing celecoxib in Colorectal Neoplasms is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About celecoxib

Celecoxib: first FDA approval 1998 (CELEBREX), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing celecoxib in Colorectal Neoplasms, or all of them as a file.
02

Study summary

This early phase IIA trial studies how well celecoxib, recombinant interferon alfa-2b, and rintatolimod work in treating patients with colorectal cancer that as spread to the liver. Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Recombinant interferon alfa-2b is a substance that can improve the body's natural response and may interfere with the growth of tumor cells. Rintatolimod may stimulate the immune system. Giving celecoxib, recombinant interferon alfa-2b, and rintatolimod may work better at treating colorectal cancer that has spread to the liver.

Read the detailed description

PRIMARY OBJECTIVES:

I. To determine the impact of a chemokine-modulatory regimen on the immune microenvironment of colorectal liver metastases, specifically the changes in the ratio between cytotoxic T-lymphocyte (CTL) marker (CD8a gene expression) to regulatory T cell (Treg) markers (FoxP3 gene expression).

SECONDARY OBJECTIVES:

I. Estimate the objective response rate of a chemokine-modulatory regimen in metastatic colorectal cancer (per Response Evaluation Criteria in Solid Tumors [RECIST] 1.1).

II. Examine the safety and tolerability profile of the combination of recombinant interferon alfa-2b (interferon alpha-2b), rintatolimod, and celecoxib when given as chemokine modulation to colorectal cancer patients prior to surgical resection using the Cancer Therapy Evaluation Program (CTEP) National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE version 4.0).

TERTIARY OBJECTIVES:

  • Estimate the median progression free survival of a chemokine-modulatory regimen in metastatic colorectal cancer
  • Estimate overall survival in participants with recurrent and/or metastatic unresectable colorectal cancer who received the chemokine-modulatory regimen
  • Comparison (using RT-PCR, immunofluorescence [IF] and immunohistochemistry [IHC] on serial sections) of the metastatic tissue specimen with regard to total numbers of infiltrating T cells, their CD4/CD8 ratios, frequencies of FoxP3 cells, and the expression of chemokine receptors on CD4+ and CD8+ T cells (CXCR3, CCR5, CCR4, CCR6, and CXCR4)
  • Evaluate the local expression of effector T cells (Teff)-attracting chemokines (CCR5, CXCL9, CXCL10 and CXCL11) and Treg-favoring chemokines (CCL22 and CXCL12) using IF and RT-PCR.

OUTLINE:

Patients receive celecoxib orally (PO) twice daily (BID), recombinant interferon alfa-2b intravenously (IV) over 20 minutes, and rintatolimod IV QD on days 1, 2,3,8,9,10,15,16 and 17 in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for up to 12 months.

03

Conditions studied

  • Metastatic Carcinoma in the Liver
  • Recurrent Colorectal Carcinoma
  • Stage IV Colorectal Cancer AJCC v7
  • Stage IVA Colorectal Cancer AJCC v7
  • Stage IVB Colorectal Cancer AJCC v7
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Recurrent and/or unresectable colorectal cancer with hepatic metastases
  • Hepatic metastases present which are amenable to
  • Prior treatment with, to or refusal of a fluoropyrimidine, irinotecan, oxaliplatin and an anti-EGFR targeted therapy (if RAS wild-type [wt]) as well as a or PD-L1 targeted drug if MSI-H/dMMR
  • No chemotherapy, radiotherapy, major surgery, or biologic therapy within 3 weeks of protocol treatment
  • An (ECOG) performance status of 0, 1, or 2
  • Have per 1.1 criteria present
  • Ability to swallow and retain oral medication
  • Participants of must agree to use adequate methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
  • >= 75,000/uL
  • >= 9 g/dL
  • Hematocrit >= 27%
  • (ANC) >= 1500/uL
  • Creatinine \< = institutional (ULN) OR
  • >= 50 mL/min for patients with creatinine levels greater than ULN
  • Total =\< 1.5 X institutional ULN or for patients with known Gilbert's Syndrome total bilirubin \<= 3 x ULN
  • (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =\< 2.5 X institutional ULN
  • Plasma amylase =\< 1.5 X institutional ULN
  • Lipase =\< 1.5 X institutional ULN
  • Participant or legal representative must understand the nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written form prior to receiving any study related procedure

Exclusion criteria

Exclusion Criteria:

  • Patients currently treated with systemic agents, including , are ineligible until 3 weeks after removal from immunosuppressive treatment
  • Patients with active disease, requiring ongoing immunosuppressive therapy or history of transplantation
  • Patients who are pregnant or nursing; women of (WOCBP) will have to undergo a urine pregnancy test as part of screening
  • Untreated central nervous system (CNS)
  • Cardiac risk factors including:

    • Patients experiencing cardiac event(s) (acute coronary syndrome, myocardial infarction, or ischemia) within 3 months of signing consent
    • Patients with a classification of III or IV
  • History of upper gastrointestinal ulceration, upper gastrointestinal bleeding, or upper gastrointestinal perforation within the past 3 years; patients with ulceration, bleeding or perforation in the lower bowel are not excluded
  • Prior allergic reaction or to celecoxib, or non-steroidal antiinflammatory drugs (NSAIDs) or any study agents which would prevent completion of protocol therapy
  • Patients are ineligible if they plan on regular use of NSAIDs at any dose more than 2 times per week (on average) or aspirin at more than 325 mg at least three times per week, on average; low-dose aspirin not exceeding 100 mg/day is permitted; patients who agree to stop regular NSAIDs or higher dose aspirin are eligible and no wash out period is required
  • Received an agent within 30 days prior to enrollment
  • Unwilling or unable to follow protocol requirements
  • Patients with known serious mood disorders
  • Any additional condition which in the investigator?s opinion deems the participant an unsuitable candidate to receive the study drugs
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    Treatment (celecoxib, interferon alfa-2b, rintatolimod)

    Patients receive celecoxib orally PO BID, recombinant interferon alfa-2b IV QD over 20 minutes, and rintatolimod IV QD on days 1, 2, 3, 8, 9, 10, 15, 16 and 17 in the absence of disease progression or unacceptable toxicity.

    Drug: Celecoxib · Other: Laboratory Biomarker Analysis · Biological: Recombinant Interferon Alfa-2b · Drug: Rintatolimod

Interventions

  • Given PO

    Also known as: Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, Celebrex, SC-58635, YM 177

  • OtherLaboratory Biomarker Analysis

    Correlative studies

  • Given IV

    Also known as: Alfatronol, Glucoferon, Heberon Alfa, IFN alpha-2B, Interferon alfa 2b, Interferon Alfa-2B, Interferon Alpha-2b, Intron A, Sch 30500, Urifron, Viraferon

  • Given IV

    Also known as: Ampligen, Atvogen

06

What researchers measure

Primary outcomes

  1. Change in Tumor-infiltrating Lymphocytes (TILs) in the Colorectal Cancer Lesions

    The TILs will be summarized by time-point (pre-/post-treatment) using the mean, median, standard deviation; and graphically using dot-plots. The TIL of interest is CD8a expression, which is reported as the mean fold change from pre-treatment (i.e. post treatment / pre treatment).

    Time frame: Baseline up to 12 months

Secondary outcomes

  1. Number of Participants With Indicated Grade Adverse Event

    Safety profile will be characterized by type, frequency, severity, timing, seriousness and relationship to study treatment. The highest grade treatment related AE is provided (per Common Terminology Criteria for Adverse Events version 4.0).

    Time frame: Up to 12 months

  2. Objective Response Rate (ORR) Assessed by Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1

    Will be treated as binary data and summarized using frequencies and relative frequencies; with the ORR estimated using a 90% confidence interval obtained using Jeffrey's prior method.

    Time frame: Up to 12 months

Other outcomes

  1. Progression Free Survival

    Will be treated as bivariate time-to-event data and will be summarized using standard Kaplan-Meier methods.

    Time frame: From the start of treatment until disease progression (defined by RECIST 1.1) or last-follow-up, assessed up to 12 months

  2. Overall Survival

    Will be treated as bivariate time-to-event data and will be summarized using standard Kaplan-Meier methods.

    Time frame: From the start of treatment until death due to any cause or last follow-up, assessed up to 12 months

07

Results

Posted Mar 2, 2022

Participant flow

Participant flow — Overall Study
MilestoneTreatment (Celecoxib, Interferon Alfa-2b, Rintatolimod)
Started19
Treated15
Completed12
Not completed7
Withdrew: Disease progression3
Withdrew: Did not meet eligibility criteria4

Outcome measures

PrimaryChange in Tumor-infiltrating Lymphocytes (TILs) in the Colorectal Cancer Lesions

The TILs will be summarized by time-point (pre-/post-treatment) using the mean, median, standard deviation; and graphically using dot-plots. The TIL of interest is CD8a expression, which is reported as the mean fold change from pre-treatment (i.e. post treatment / pre treatment).

Time frame:
Baseline up to 12 months
Reported as:
Mean · fold change
Change in Tumor-infiltrating Lymphocytes (TILs) in the Colorectal Cancer Lesions
fold changeTreatment (Celecoxib, Interferon Alfa-2b, Rintatolimod)
Change in Tumor-infiltrating Lymphocytes (TILs) in the Colorectal Cancer Lesions7.25 ± 13.79
Statistical analysis
  • Treatment (Celecoxib, Interferon Alfa-2b, Rintatolimod) · t-test, 1 sided · p = 0.046 (significance level = 0.05)df = 11. one-sided as post treatment increases were of interest. the fold changes were log-transformed prior to inferences.
SecondaryNumber of Participants With Indicated Grade Adverse Event

Safety profile will be characterized by type, frequency, severity, timing, seriousness and relationship to study treatment. The highest grade treatment related AE is provided (per Common Terminology Criteria for Adverse Events version 4.0).

Time frame:
Up to 12 months
Reported as:
Count of participants · Participants
Number of Participants With Indicated Grade Adverse Event
ParticipantsTreatment (Celecoxib, Interferon Alfa-2b, Rintatolimod)
No Treatment Related AE Reported1
Grade I6
Grade II7
Grade III1
Grade IV0
Grade V0
SecondaryObjective Response Rate (ORR) Assessed by Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1

Will be treated as binary data and summarized using frequencies and relative frequencies; with the ORR estimated using a 90% confidence interval obtained using Jeffrey's prior method.

Time frame:
Up to 12 months
Reported as:
Count of participants · Participants
Objective Response Rate (ORR) Assessed by Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1
ParticipantsTreatment (Celecoxib, Interferon Alfa-2b, Rintatolimod)
Objective Response Rate (ORR) Assessed by Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.10
Other pre-specifiedProgression Free Survival

Will be treated as bivariate time-to-event data and will be summarized using standard Kaplan-Meier methods.

Time frame:
From the start of treatment until disease progression (defined by RECIST 1.1) or last-follow-up, assessed up to 12 months
Reported as:
Median · Months
Progression Free Survival
MonthsTreatment (Celecoxib, Interferon Alfa-2b, Rintatolimod)
Progression Free Survival1.5 (1.4 to 1.8)
Other pre-specifiedOverall Survival

Will be treated as bivariate time-to-event data and will be summarized using standard Kaplan-Meier methods.

Time frame:
From the start of treatment until death due to any cause or last follow-up, assessed up to 12 months
Reported as:
Median · Months
Overall Survival
MonthsTreatment (Celecoxib, Interferon Alfa-2b, Rintatolimod)
Overall Survival10.5 (2.2 to 15.2)

Adverse events

Collected over Adverse event data was collected up to 30 days after end of treatment, up to 1 year.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment (Celecoxib, Interferon Alfa-2b, Rintatolimod)8/15 (53.3%)3/15 (20%)14/15 (93.3%)
Most frequent serious events
Most frequent serious events
EventTreatment (Celecoxib, Interferon Alfa-2b, Rintatolimod)
HyperbilirubinemiaHepatobiliary disorders1/15
Pleural EffusionRespiratory, thoracic and mediastinal disorders1/15
Neoplasm (NOS)Neoplasms benign, malignant and unspecified (incl cysts and polyps)1/15
DeathGeneral disorders1/15
Most frequent other events
Showing 10 of 28
Most frequent other events
EventTreatment (Celecoxib, Interferon Alfa-2b, Rintatolimod)
ChillsGeneral disorders11/15
FatigueGeneral disorders11/15
Hot flushVascular disorders6/15
PyrexiaGastrointestinal disorders5/15
Decreased appetiteMetabolism and nutrition disorders5/15
NauseaGastrointestinal disorders4/15
Gastrointestinal disorders **Any AE - Maximum Grade Seen DiarrhoeaGastrointestinal disorders3/15
HeadacheNervous system disorders3/15
VomitingGastrointestinal disorders2/15
Blood alkaline phosphatase increasedInvestigations2/15

Baseline characteristics

There were 19 patients accrued to the study; however, 4 never received any treatment and became ineligible.

Age, Continuous
Age, Continuous(years)Treatment (Celecoxib, Interferon Alfa-2b, Rintatolimod)
Mean60.5 ± 9.9
Sex: Female, Male
Sex: Female, Male(Participants)Treatment (Celecoxib, Interferon Alfa-2b, Rintatolimod)
Female3
Male12
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment (Celecoxib, Interferon Alfa-2b, Rintatolimod)
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American1
White14
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Treatment (Celecoxib, Interferon Alfa-2b, Rintatolimod)
United States15
Line of Treatment
Line of Treatment(Participants)Treatment (Celecoxib, Interferon Alfa-2b, Rintatolimod)
Third Line5
Fourth Line6
Fifth or More Line4
Clinical Stage
Clinical Stage(Participants)Treatment (Celecoxib, Interferon Alfa-2b, Rintatolimod)
Stage I0
Stage II0
Stage III0
Stage IV15
Not Reported0
Location of Disease
Location of Disease(Participants)Treatment (Celecoxib, Interferon Alfa-2b, Rintatolimod)
Cecum1
Colon, NOS7
Rectum, NOS6
Sigmoid Colon1
Prior Radiation
Prior Radiation(Participants)Treatment (Celecoxib, Interferon Alfa-2b, Rintatolimod)
Count of participants6

2 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2018 to primary completion in Dec 2020, 32 months.

Results were first posted in Mar 2022, 1 year 2 months after primary completion.

Of 498 non-industry phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 75. This study's 32 months is below that.

Counting every sponsor, half of 618 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2018
First posted
Jan 18, 2018
StartActual
Apr 19, 2018
Primary completionActual
Dec 23, 2020
CompletionActual
Aug 29, 2021
Results first posted
Mar 2, 2022
Last update
Mar 2, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03403634
Responsible party
Sponsor
First posted
Jan 18, 2018
Start date
Apr 19, 2018
Primary completion
Dec 23, 2020
Completion
Aug 29, 2021
Results posted
Mar 2, 2022
Last update
Mar 2, 2022

Study contacts

Sarbajit Mukherjee, MD
principal investigator · Roswell Park Cancer Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Celecoxib · Interferon alpha-2 · poly(I).poly(c12,U)

Start the discussion